remimazolam (Byfavo)
Jump to navigation
Jump to search
Indications
- sedations in adults
Contraindications
- < 18 years of age
- hypersensitivity reaction to dextran 40
- caution in geriatric patients & patients with severe liver disease
Dosage
adults:
- 5 mg IV push over 1 minute
- supplemental doses of 2.5 mg IV over 15 seconds
- >= 2 minutes between doses
* single-use vial containing 20 mg BYFAVO (remimazolam) lyophilized powder for reconstitution, equivalent to 27.2 mg remimazolam besylate
Adverse effects
- > 10%
other
* flumazenil should be immediately available during administration
- drug adverse effects of benzodiazepines
- drug adverse effects of psychotropic agents
- drug adverse effects of sedatives
Drug interactions
- coadministration of CNS depressants, including opioids, other benzodiazepines, & propofol.
- drug interaction(s) of methadone in combination with benzodiazepines
- drug interaction(s) of benzodiazepines with antidepressants
- drug interaction(s) of benzodiazepines with thiazide diuretics
- drug interaction(s) of antipsycotics with benzodiazepines
- drug interaction(s) of antidepressants with benzodiazepines
- drug interaction(s) of beta-adrenergic receptor antagonists with benzodiazepines
- drug interaction(s) of beta-adrenergic receptor antagonists (except atenolol) with benzodiazepines
- drug interaction(s) of alcoholic beverage with benzodiazepines
- drug interaction(s) of benzodiazepine with opiates
Mechanism of action
- combines effects of midazolam &
More general terms
References
- ↑ Goudra BG, Singh PM. Remimazolam: The future of its sedative potential. Saudi J Anaesth. 2014 Jul;8(3):388-91. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25191193 Free PMC article
- ↑ Wikipedia: Remimazolam https://en.wikipedia.org/wiki/Remimazolam
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION BYFAVOTM (remimazolam) for injection, for intravenous use, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf